James Larkin COSA 2015 ASM

Abstracts this author is presenting:

• Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067) — Posters1